In this protocol, we describe how to explore immune function in radiation-induced anti-tumor abscopal effect (ATAE) in PD-L1-deficient (PD-L1<sup>−/−</sup>) mice. We detail steps for primary and abscopal tumor model establishment in mice, tumor fractional irradiation scheme, and isolation of single cells from tumor tissues. Furthermore, we describe the analysis of the proportion of immune cells infiltrated in tumors and the specific staining of cytokines released from immune cells to confirm the ability of CD8+ T cells in killing tumors.

Publisher’s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics.
Immunostaining of tumor-infiltrating immune-cell-related markers and cytokines in the tumor fractional radiation model of host PD-L1-deficient mice

Xinrui Zhao¹,² and Chunlin Shao¹,³,*

¹Institute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China
²Technical contact: 19111140003@fudan.edu.cn
³Lead contact
*Correspondence: clshao@shmu.edu.cn
https://doi.org/10.1016/j.xpro.2022.101859

SUMMARY

In this protocol, we describe how to explore immune function in radiation-induced anti-tumor abscopal effect (ATAE) in PD-L1-deficient (PD-L1⁻/⁻) mice. We detail steps for primary and abscopal tumor model establishment in mice, tumor fractional irradiation scheme, and isolation of single cells from tumor tissues. Furthermore, we describe the analysis of the proportion of immune cells infiltrated in tumors and the specific staining of cytokines released from immune cells to confirm the ability of CD8+ T cells in killing tumors. For complete details on the use and execution of this protocol, please refer to Zhao et al. (2022).¹

BEFORE YOU BEGIN

Radiotherapy is conventionally applied in antagonizing primary tumors and metastases.²,³ Currently, the combination of radiotherapy with immunotherapy is increasingly attracted the attentions in the study of radiation-induced anti-tumor abscopal effect (ATAE).⁴,⁵ Exploring the change of tumor microenvironment and the crucial functions of immune cells in the processes of anti-tumor is of great significance to improve the efficacy of radioimmunotherapy (RIT). This protocol gives a step-by-step guidance for the construction of xenograft tumor model and fractional irradiation model, the isolation of single cells from tumor tissues to detect the ratio of immune cells infiltrated in the tumors, and the measurement of cytokines released from CD8+ T cells.

Institutional permission

All animal experiments were approved by the Animal Welfare and Ethics Committee of Fudan University.

Culture of Lewis lung carcinoma (LLC) cells

- Timing: 1 week

1. Thaw of frozen LLC cells.
   a. Take out the frozen LLC cells from the liquid nitrogen tank.
   b. Place them in a 37°C water bath immediately, and shake them quickly to accelerate the melting of cells.
   c. Put the melted cryopreservation tube into the centrifuge immediately.
   d. Centrifuge at 100 g for 4 min.
e. Discard the supernatant,
f. Add 1 mL of complete DMEM medium (supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin) to resuspend the cells.
g. Transfer the cell suspension to a 10-cm culture dish supplemented with 7 mL medium.
h. Place cells in an incubator for further culture under 5% CO₂ at 37°C.

2. Cell passage.
a. Observe LLC cells under an inverted microscope. When the cell density reaches 80%–90% confluence, discard the culture medium and wash the cell with PBS gently for 2–3 times.
b. Discard PBS buffer.
c. Add 1 mL trypsin along the dish wall slowly, shake the dish gently and evenly, place the dish in a 37°C incubator for about 1 min.
d. Add 1 mL complete medium to terminate the digestion when the cells shrink and become round observed under a microscope.
e. Dissociate the cells with plastic pipette gently.
f. Collect the cells into a 15 mL centrifuge tube.
g. Centrifuge at 100 g for 5 min.
h. Discard the supernatant.
i. Add 1 mL complete medium to resuspend cells.
j. Take about one-third of the cells into a 10-cm dish containing 10 mL medium, and shake the dish.
k. Put the cells in a 5% CO₂ cell incubator for further culture at 37°C.

Note: When the cells grow to nearly 100% confluence in the 10-cm culture dish, the number of cells is about $1 \times 10^7$ cells.

Genotyping of mice

© Timing: 5–6 h

Male PD-L1 wide type (wt) and PD-L1⁻/⁻ C57BL/6J mice (7–8 weeks) purchased from Shanghai Model Organisms Center (Shanghai, China) were used in this protocol. The offsprings of mice are genotyped before each experiment. The experimental procedures are shown in Figure 1A.

3. Label each experimental mouse with ear-tag.
a. Grasp the skin of the mouse neck with one hand.
b. Pass the labeled ear-tag through the middle of one ear of the mouse quickly and accurately with an ear mark plier.

Note: Put the ear tag plier as close to the root of the mouse ear as possible to avoid the mouse scratching the ear-tag off.

4. Hold the mouse tightly with one hand, and cut off the tail end (0.5 cm in length) with scissors, and put it into a 1.5 mL centrifuge tube on ice.
5. Mouse tail tissues were lysed using Mouse Direct PCR Kit (containing Buffer L and Protease Plus) to extract genomic DNA. Add 100 μL lysate (Buffer L: Protease Plus=50: 1) to each tube.
6. Put the sample tube in a water bath and lysed the tissue at 55°C for 30 min.
7. Put the EP tube in the metal bath at 95°C for 5 min to inactivate the protease.
8. Centrifuge the sample at 25°C at 300 g for 5 min and transfer the supernatant containing genomic DNA to a new EP tube.
9. Store the supernatant at −20°C immediately, or conduct PCR assay as below.
10. Mix the genomic DNA sample with primers for PCR assay.
a. Set up the PCR reaction system.
b. Run the PCR instrument.

c. Set up the PCR reaction system.

d. Run the PCR instrument.

11. Dissolve agarose powder in TAE buffer to prepare 1.5% agarose gel (add 0.01% gel containing YeaRed Nucleic Acid Gel Stain),
12. Run agarose gel electrophoresis at a constant pressure of 100 v/cm for 50 min.
13. Observe the band positions with a gel imager. The relationship between the band positions and PD-L1 genotypes is shown below.
a. PD-L1 wild type (PD-L1+/+): only 642 bp band.
b. PD-L1 heterozygote (PD-L1+/-): both 642 bp and 1,026 bp bands.
c. PD-L1 homozygote (PD-L1/C0/C0): only 1,026 bp band.

The characteristic DNA band images of different PD-L1 genotypes are shown in Figure 1B.
Figure 1. Schematic diagram of the identification of mouse genotype
(A) The mouse genotypes can be identified by PCR assay of its genomic DNA extracted from tail tissue.
(B) Typical DNA electrophoretic bands of the tail tissue of mice with different PD-L1 genotypes.

KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| FITC anti-mouse CD3ε (1:250) | Biolegend | Cat # 100306, RRID: AB_312671 |
| PE anti-mouse CD4 (1:200) | Biolegend | Cat # 100408, RRID: AB_312693 |
| APC anti-mouse CD8α (1:200) | Biolegend | Cat # 100712, RRID: AB_312751 |
| PE/Cyanine7 anti-mouse NK-1.1 (1:200) | Biolegend | Cat # 108713, RRID: AB_389363 |
| PE anti-mouse CD279 (PD-1) (1:200) | Biolegend | Cat # 135205, RRID: AB_1877232 |
| PE/Cyanine7 anti-mouse/human CD44 (1:200) | Biolegend | Cat # 103029, RRID: AB_830786 |
| APC/Cyanine7 anti-mouse CD62L (1:200) | Biolegend | Cat # 104427, RRID: AB_830798 |
| PE/Cyanine7 anti-mouse IFN-γ (1:100) | Biolegend | Cat # 505825, RRID: AB_1595591 |
| Purified anti-mouse IFNAR-1 | Biolegend | Cat # 127322, RRID: AB_11149116 |
| TruStain FoxP3 PLUS (anti-mouse CD16/32) (1:200) | Biolegend | Cat # 156603, RRID: AB_2783137 |

| **Chemicals, peptides, and recombinant proteins** |        |            |
|--------------------------------------------------|--------|------------|
| Hydroxychloroquine sulfate (HCO) | MedChemExpress | Cat # HY-B1370 |
| Pentobarbital sodium | Sigma | Cat # 11715 |
| Collagenase IV | YEASEN | Cat # 40510ES60 |
| Deoxyribonuclease I (DNase I) | YEASEN | Cat # 10607ES15 |

(Continued on next page)
**MATERIALS AND EQUIPMENT**

### REAGENT or RESOURCE SOURCE IDENTIFIER

| REAGENT or RESOURCE                     | SOURCE         | IDENTIFIER |
|-----------------------------------------|----------------|------------|
| Mouse Direct PCR Kit                    | Bimake         | Cat # B40013 |
| Agarose                                 | Beyotime       | Cat # ST004Q |
| YeasRed Nucleic Acid Gel Stain          | YEASEN         | Cat # 10202E576 |
| Fixation Buffer                         | Biolegend      | Cat # 420801 |
| Intracellular Staining Permeabilization Wash Buffer | Biolegend      | Cat # 421002 |
| Cell Stimulation Cocktail               | Invitrogen     | Cat # 00-4975-93 |
| 2x M-PCR OPTI™ Mix (Dye Plus)           | Bimake         | Cat # B45012 |
| Dulbecco’s Modified Eagle Medium        | Gibco          | Cat # 11965118 |
| RPMI 1640                                | Gibco          | Cat # 11875176 |
| Fetal bovine serum                      | Gibco          | Cat # 16000-044 |
| Trypsin                                 | Gibco          | Cat # 25200072 |
| 70 µm cell strainer                     | SPL life science | Cat # SPL-93070 |

**Experimental models: Cell lines**

| LLC cell line                           | American Type Culture Collection | Cat # CRL-1642, RRID: CVCL_4358 |

**Experimental models: Organisms/strains**

| Mouse: C57BL/6J PD-L1+/− (6–8 weeks, Male) | Shanghai Model Organisms Center | N/A |

**Oligonucleotides**

| Primer       | Cat/RRID   | Sequence               |
|--------------|------------|------------------------|
| PD-L1 primer 1 | N/A        | AGCTTTGGGTGTGGTTAGTAGTA |
| PD-L1 primer 2 | N/A        | GGCTCTCCCTCGAAAGTTG |
| PD-L1 primer 3 | N/A        | GCTACTGCACCTGGCTTCTACCTG |
| PD-L1 primer 4 | N/A        | TACCTATCCCCTGCACCATGACCT |

**Software and algorithms**

| Software       | RRID       |
|----------------|------------|
| GraphPad Prism 8 | SCR_008520 |
| FlowJo         | N/A        |

---

### 1 × PBS buffer

| Reagent         | Amount       | Final concentration |
|-----------------|--------------|---------------------|
| 10 × PBS        | 100 mL       | 1×                  |
| RNase-free water| 900 mL       | N/A                 |

Store at 4°C for up to 1 year.

### 50 × Tris acetate electrophoresis buffer (TAE)

| Reagent          | Amount       | Final concentration |
|------------------|--------------|---------------------|
| Tris base        | 242 g        | 2 M                 |
| Acetic acid (glacial) | 57.1 mL   | 1 M                 |
| 0.5 M EDTA pH 8.0 | 100 mL      | 50 mM               |
| RNase-free water | To 1,000 mL  | N/A                 |

Store at 25°C for up to 6 months.

### 1 × TAE

| Reagent          | Amount       | Final concentration |
|------------------|--------------|---------------------|
| 50 × TAE         | 20 mL        | 1×                  |
| RNase-free water | 980 mL       | N/A                 |

Store at 25°C for up to 6 months.
STEP-BY-STEP METHOD DETAILS

Construction of primary and abscopal tumor model in mice

© Timing: 4 days

1. Cut off the hair of the left and right flanks of mice to expose the skin.
2. Preparation of cell suspension.
   a. Take the LLC cells seeded in 10-cm dishes from the cell incubator to the biosafety cabinet gently and discard the culture medium.
   b. Add 1 mL PBS buffer and wash for 1–2 times gently.
   c. Discard the PBS buffer.
   d. Add 1 mL trypsin and put it in cell incubator for 1 min to digest cells.
   e. Add 1 mL complete DMEM medium to stop the process of digestion when the cells shrink and become round observed under a microscope.
   f. Collect the dissociated cells into 15 mL centrifuge tubes.
   g. Centrifuge at 100 g for 5 min.
   h. Discard the supernatant.
   i. Add 1 mL PBS buffer to resuspend the cells and take out 100 μL cell suspension to count cells with cell counter.
   j. Adjust the cell concentration to $2 \times 10^7$ cells/mL with PBS buffer in a 5 mL centrifuge tube.
   k. Put the tube on the ice immediately.

   Note: Enough cells need to be prepared in advance according to the requirement of tumorigenesis.

3. Mix the cells evenly.
   a. Take 100 μL of the cell suspension with 1 mL syringe,
   b. Inject this cell suspension into the right flank of the mouse subcutaneously.

   Note: make sure that the amount of cells injected into each mouse is $2 \times 10^6$ cells.

   c. Label the formed xenograft as the primary tumor. This day is recorded as day 0.

   Note: The cells should be injected subcutaneously within 30 min after suspension.

   CRITICAL: The number of tumor cells inoculated to mice should be adjusted according to the immune character of mice and the type of tumor cell line. If the tumorigenicity of cells is poor, the number of tumor cells can be appropriately increased, but not more than $1 \times 10^7$ cells/mouse. The number of mice in each group can also be increased to exclude individual differences.

4. On the day 3, prepare LLC cells with a concentration of $2 \times 10^7$ cells/mL as the step 2.
5. Inject 100 μL cell suspension subcutaneously into the left flank of above mouse to generate the abscopal xenograft tumor.

---

| FACS buffer (500 mL) | Amount | Final concentration |
|----------------------|--------|---------------------|
| 1x PBS               | 490 mL | N/A                 |
| FBS                  | 10 mL  | 2%                  |
| 0.5 M EDTA solution (PH=8) | 200 μL | 2 mM                |

Store at 4°C for up to 6 months.
6. After the completion of tumor inoculation, the mice are fed normally, and the tumor volumes on both flanks are recorded every two days with a digital caliper until the mice are killed.

Note: For tumor measurements, the tumor volume is calculated with a formula $V = \frac{\text{width}^2 \cdot \text{length}}{2}$.

**Drug administration**

○ **Timing:** 30 min

7. When the primary tumor volume reaches to about 50 mm$^3$, the PD-L1 wt and PD-L1$^{-/-}$ mice are divided into 7 groups including control, anti-IFNAR-1, HCQ, IR, IR+ anti-IFNAR-1, IR+ HCQ, and IR+ HCQ+ anti-IFNAR-1. Six mice each group.

Note: In this experiment, the mice were grouped on the day 9 after the injection of primary tumor.

8. Label the mice genotypes, mice number, and treatment methods on an information card of each cage.

9. One day before irradiation, administer anti-IFNAR-1 (500 μg per mouse)$^7$ into mice by intraperitoneal injection.

△ CRITICAL: The anti-IFNAR-1 should be administered quickly to ensure the valence of antibody, and the antibody should be injected within 30 min.

**Tumor fractional irradiation and drug administration model**

○ **Timing:** 3 days

On the day 10 after cell injection, the primary tumor with a volume of about 50 mm$^3$ (Figure 2A) is irradiated with a total dose of 24 Gy X-rays in 3 fractions in 3 consecutive days (8 Gy × 3).

10. Calculate the average weight of mice administrated with HCQ solution.
Note: The experimental mice are weighed and M (g) is set as the mass of each mouse, the number of mice requiring HCQ administration is represented as n, the value of average weight is recorded as $\bar{M} = \frac{1}{n} \sum_{i=1}^{n} M_i$ (g).

11. Calculate the amount of the corresponding reagent.

Note: The dosage of hydroxychloroquine sulfate (HCQ) in this protocol is 50 mg/kg and the required total mass of HCQ powder (m) is calculated as the formula, $m = 0.05 \bar{M} \times n$ (mg), 100 μL HCQ solution needs to be given at the weight of mice is $\bar{M}$, hence, the total mass of HCQ powder needs to be dissolved in $100 \times n$ μL saline.

12. Weigh the calculated mass of HCQ powder with electronic balance.
13. Dissolve the HCQ powder with saline in the 5 mL EP tube.

Note: Prepare the HCQ solution fresh and used it after fully dissolution.

14. Calculate the volume of HCQ solution injected into each mouse.

Note: The volume of HCQ solution injected into each mouse is calculated by using the formula, $V_n = \frac{\bar{M}}{M} \times 100$ (μL), and record the value of HCQ solution injected into each mouse. The other mice are given saline as control.

15. Suction off HCQ solution or saline with 1 mL syringe.
16. Inject 100 μL HCQ solution or saline intraperitoneally into mice.
17. Irradiate mice with X ray two hours after drug administration.
   a. Inject 1% pentobarbital sodium intraperitoneally into mice with a dose of 50 mg/100 g for anesthesia.
   b. Put the mouse into a lead mold after the anesthetic takes effect (about 5–10 min).
   c. Clamp out the tumor with tweezers gently, and shield the rest with lead plates (the thickness of lead plate is greater than 1 cm), as shown in Figure 2B.
   d. Irradiate the tumor of mice with 8 Gy X ray.
18. Observe the state of mice closely after irradiation, until all mice wake up.
19. Carry out the same administration of HCQ and irradiation protocols as above in the next two days.

Note: During these three days, to keep the same time point of daily administration, the HCQ administration are all conducted 2 h before irradiation.

Preparation of single cell suspension from tumor tissue

⏱ Timing: 5–6 h

20. Kill the mice and strip out the transplanted tumor after 21 days of the first tumor cell injection,
   a. Sacrifice the mice by neck breaking as quick as possible to alleviate the pain of mice.
   b. Pin down mouse on its back using needles.
   c. Spray the mouse body with 75% ethanol.
   d. Cut the mouse skin from the area near the bottom of abdomen to neck with scissors.
   e. Strip out the tumor capsule with a tweezer and dissect out the tumor gently.
   f. Clean the tumor and put it into the marked 50 mL conical tube containing PBS buffer.

Note: All the surgical tools should be autoclaved before use. 50 mL centrifuge tubes have been marked in advance according to the different treatment methods of mice and tumor tissue should be immersed in PBS buffer.
21. Weigh tumor, then cut it into small pieces less than 1 mm and transfer the tumor tissues into a 50 mL conical tube.

22. Add RPMI medium supplemented with 2% FBS to the 50 mL conical tube, 1 mL medium per 1 mg tissue.

23. Add an appropriate amount of collagenase IV into the 50 mL conical tube to a final concentration of 1 mg/mL.

24. Put the conical tube into a shaking bath at 37°C until the tissue is digested.

*Note:* The time required varies with the type of tumor, but should not exceed 1.5 h to limit the cell viability.

25. Pass the tissue homogenate through a 70 µm cell strainer into a new 50 mL conical tube, and clean the strainer several times with serum-free RPMI.

26. Add DNase into the homogenate and incubate at 37°C for 15 min if the tissue homogenate appears to be caked.

*Note:* The final concentration of DNase is 10 µg/mL.

27. Collect the cells from tissue homogenate after centrifugation at 400 g for 5 min and resuspend with PBS buffer.

28. Take a small portion of cells for counting and add PBS buffer to adjust the cell density to $1 \times 10^7$ cells/mL.

29. Preparation of cells for immunostaining.
   a. For the staining of cell surface antigen, add 100 µL of cell suspension to 1.5 mL EP tubes, $10^6$ cells per tube.
   b. For the staining of intracellular cytokine, the $2 \times 10^6$ cells are resuspended with 500 µL RPMI medium supplemented with 10% FBS, add 1 µL cell stimulation cocktail (containing protein transport inhibitors) in the cell suspension.
   c. Plate the cell suspension in a 12-well plate and culture cells in an incubator containing 5% CO$_2$ at 37°C for 16 h.

   △ CRITICAL: For the cells that need to be used for subsequent culture, the process of preparing single cells from tissues need to be carried out in a biosafety cabinet.

**Cell surface antigen staining**

◎ Timing: about 1 h

30. Resuspend cells with 100 µL FACS buffer.

31. Pre-incubate with Fc receptor blocker (TruStain FcX™ PLUS) for 5–10 min on ice, 0.25 µg/10^6 cells in 100 µL FACS buffer.

32. Add fluorescence-labeled antibodies to stain the cells and keep away from light. The reference antibody concentrations are: Anti-CD3 (2 µg/mL), anti-CD4 (1 µg/mL), anti-CD8 (1 µg/mL), anti-NK1.1 (1 µg/mL), anti-CD44 (1 µg/mL), anti-CD62L (1 µg/mL), and anti-PD-1 (1 µg/mL).

   a. For the samples of the experimental group, due to the overlapping fluorescence labeling and wavelength of antibodies, the mixing scheme of antibodies is divided into the following two groups:
      i. Anti-CD3, anti-CD4, anti-CD8, anti-NK1.1.
      ii. Anti-CD3, anti-CD8, anti-CD44, anti-CD62L, anti-PD-1.
   b. For the samples of single staining group, we add the sample cells of specific group to 7 EP tubes, respectively, 50 µL cell suspension per tube. Add one antibody (anti-CD3, anti-CD4, anti-CD8, anti-NK1.1, anti-CD44, anti-CD62L, or anti-PD-1) to each EP tube, and the amount of antibody is half of the amount of corresponding antibody in the experimental group.
Note: The whole process of staining should be kept away from light to avoid the loss of fluorescence.

⚠ CRITICAL: Antibodies with intersecting fluorescence wavelengths can’t be used to stain cells in the same tube. Each antibody needs to be set with a single staining tube to adjust the fluorescence compensation. In the single staining group, the specific group refers to the experimental group with the highest antigen expression inferred from the pre-experiment, which can ensure that there is a fluorescence signal during fluorescence modulation compensation.

33. Stain the sample at 4°C for 30 min in the dark.
34. Centrifuge at 400 g for 5 min to remove the supernatant.
35. Add 1 mL FACS buffer to wash cells, centrifuge at 400 g for 5 min to remove the supernatant.
36. Add 400 μL FACS buffer to resuspend cells in preparation for flow cytometry analysis.

### Intracellular cytokine staining

⏱ Timing: 2–3 h

37. Collect the cells and centrifuge at 400 g for 5 min to remove the supernatant after 16 h of cell stimulation.
38. Add 500 μL FACS buffer to wash cells, centrifuge at 400 g for 5 min to remove the supernatant.
39. Resuspend cells with 100 μL FACS buffer.
40. Pre-incubate with Fc receptor blocker (TruStain FcX™ PLUS) for 5–10 min on ice, 0.25 μg/10^6 cells in 100 μL FACS buffer.
41. Add CD8 fluorescent antibody (1 μg/mL) to stain cells in dark condition for 30 min at 4°C. This step is the same as that of staining cell surface antigen.

Note: The whole process of staining should be kept away from light to avoid the loss of fluorescence.

⚠ CRITICAL: If the cells are not sorted, cells need to be stained with antibodies of cell surface marker in advance.

42. Add 1 mL FACS buffer to each tube to wash the cells, and centrifuge at 400 g for 5 min to remove the supernatant.
43. Add 100 μL fixation buffer to fix the cells at 4°C for 20 min.

Note: The purpose of this step is to stabilize the binding of antibodies and antigens on the surface of cell membrane.

44. Centrifuge at 400 g for 5 min to remove the supernatant.
45. Resuspend cells with 100 μL 1× perm/wash buffer.

Note: The main function of perm buffer is to break the cell membrane and clean cells.

46. Add fluorescence-labeled antibody to stain the cell cytokines in dark condition. The reference antibody concentration is 2 μg/mL for IFN-γ.
47. After adding the antibody, stain the sample at 4°C for 30 min in the dark.
48. Add 500 μL 1× perm/wash buffer to wash cells, centrifuge at 400 g for 5 min to remove the supernatant.
49. Add 400 μL FACS buffer into the cells for flow cytometry analysis.
Flow cytometry analysis

© Timing: about 30 min

50. Filter the single cell suspension with a 200-mesh filter membrane and place them in the flow tubes.

51. Adjust the fluorescence compensation with single staining tube. The operation of adjusting fluorescence compensation is as follows, taking the detection of CD3, CD4 and CD8 indicators as an example.
   a. According to the required staining indicators, make a pair combination and set the X-Y plot on the computer in advance. When the number of indicators is n, the total number of plots is $3 \times (n-2)$.
   b. Collect the cells of the single staining tube respectively, and adjust the compensation value, so that there is a detection signal on the staining channel and no signal on other non-staining channels. The compensation plots of each single staining tube are shown in Figure 3.

Note: Fluorescence of all detected single staining samples cannot be in the same fluorescent channel.

52. Analyze cell samples with a flow cytometry. For samples stained only on the cell surface, collect $1 \times 10^5$ cells. For the cell samples for detecting intracellular factors, collect $5 \times 10^4$ cells.

Figure 3. Adjustment of the fluorescent compensation by single staining tube
(A–C) Set CD3 vs CD4, CD3 vs CD8, CD4 vs CD8 gate respectively, adjust fluorescent compensation with single staining tubes of CD3 (A), CD4 (B) and CD8 (C).
The number of cells used for flow cytometric analysis is not fixed. In tumor cells, due to the small proportion of some infiltrating immune cells, the number of collected samples should be expanded in order to be able to detect certain populations.

53. The detailed gating strategy shown as Figures 4 and 5.
   a. Set the initial FSC vs SSC gate to circle the lymphocyte population (Figures 3A and 4A).

   Note: In this step, we have carefully circled the main cell cluster, largely excluding the stray cells and dead cells.

   b. Set FSC-H vs FSC-W (B) and SSC-H vs SSC-W gate (C) to remove adherent cells.

   CRITICAL: The cell population with constant height (H) and increased width (W) are adherent cells.

   c. Set CD3 vs SSC gate to circle the CD3+ T lymphocytes (Figures 4D and 5D).
   d. Set CD4 vs CD8 gate to circle the CD4+ T lymphocytes and CD8+ T lymphocytes (Figure 4E); Set CD8 vs SSC gate to circle the CD8+ T lymphocytes (Figure 5E).
   e. Gated CD8+ T lymphocytes. Set CD8 vs PD-1 gate to circle CD8+PD-1+ T lymphocytes (Figure 4F); Set CD62L vs CD44 gate to circle CD44+CD62L- T lymphocytes (Figure 4G); Set CD8 vs IFN-γ to circle CD8+PD-1+ T lymphocytes (Figure 5F).

   Note: In the process of flow cytometric detection, operate under dark condition.
Analyze the sorting results with FlowJo software. The analysis results of the proportion of tumor-infiltrated immune cells and the proportion of IFN-γ released by CD8+ T cells are presented in Figures 3 and 4, respectively.

**Note:** In the process of flow cytometry analysis, operate under dark condition.

### EXPECTED OUTCOMES

According to previous research, the fractional irradiation scheme of 8 Gy×3 can effectively induce ATAE. In this protocol, we provided reliable construction method of primary tumor and abscopal tumor model and fractional irradiation model in mice, as well the detailed dosage regimen of drugs that further affected ATAE effectively.

Based on the protocol of single cell isolation by digesting tumor tissue, the effects of fractionated irradiation and drug treatment on the proportions of infiltrated immune cells in mice xenograft tumors are detected by flow cytometry assay.

### LIMITATIONS

One of the limitations is that, in our experiment, we explore the ATAE by constructing the bilateral tumor model rather than the spontaneous metastatic tumor model due to the low success rate in
constructing the model of spontaneous metastasis, which has limitation on the effect of simulating the clinical ATAE. In addition, we only identified the function of CD8+ T cells and the production of cytokines released by CD8+ T cells by labeling surface antigens, but did not sort out the CD8+ T cells infiltrated in the tumors to detect relevant indicators because of the low proportion of infiltrated CD8+ T cells in tumors. Therefore, it is worthwhile to explore more feasible solutions to solve the technical obstacles in future.

**TROUBLESHOOTING**

**Problem 1**
During PCR assay, the DNA bands in agarose gel are too weak to be observed.

**Potential solution**
Improve experimental conditions. Use new primers and store it in a short period if necessary. Increase the amount of cDNA and/or the number of PCR cycles (30–35 cycles) appropriately, or reduce the annealing temperature.

**Problem 2**
Low tumor formation rate or no tumor formation after tumor cell inoculation.

**Potential solution**
Insufficient cell viability or low inoculation density will affect the tumor formation efficiency in mice. It’s necessary to conduct a pre-experiment to determine the optimal amount of cells that can form tumors in mice in advance. Cells should be inoculated in the shortest time after digestion and place on ice to ensure viability. Some kind of cells are difficult to form tumors, in this case, mix the Matrigel with cell suspension (Matrigel: PBS=1: 1) to improve the tumor formation rate.

**Problem 3**
The tumor sizes formed by inoculating the same number of tumor cells in the same experimental group of mice are significantly different.

**Potential solution**
The reason for this difference in tumor size may be that the tumor cells are not evenly mixed during the inoculation, or the tumor cells flow out after the injection resulting in not all of them being inoculated subcutaneously. In this case, gently flick the EP tube and syringe tube wall to mix the cells well before inoculating the cells into mice, and do not mix cells too violently to avoid mechanical damage to cells.

**Problem 4**
The amount of single cells isolated from tumor tissue is less than expected number.

**Potential solution**
In the process of isolating single cells from tumor tissue, the tumor tissue should be cut as small as possible so that it can be fully digested by collagenase and DNase. Ensure that the digestion time of collagenase is less than 1.5 h to prevent excessive digestion leading to cell death.

**Problem 5**
Weak immunofluorescence signals in the process of flow cytometry analysis of cell surface markers.

**Potential solution**
Increase the corresponding antibody concentration or staining time, or replace the antibody labeling with stronger fluorescence (such as using the fluorescein of phycoerythrin (PE) and allophycocyanin (APC), or apply the antibody produced by different manufacturers.
Problem 6
In the process of cell staining, we carefully circled the main cell cluster, which largely excluded the stray cells and dead cells. Meanwhile, considering that there were many staining indicators in our experimental scheme and the fluorescent signals would interfere with each other, so we did not use the live/dead dyes to stain the cells. But for the rigor of the experiment, live/dead cell staining may necessary, which can eliminate the interference of dead cells.

Potential solution
Select appropriate live/dead dyes according to suitable live/dead dyes according to the principle that the fluorescent channels do not interfere with each other, and stain the samples with live/dead dyes according to the manufacturer’s instructions.

RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Chunlin Shao, clshao@shum.edu.cn.

Materials availability
This study did not generate new unique reagents.

Data and code availability
This study did not generate or analyze datasets.

ACKNOWLEDGMENTS
This work was supported by the National Natural Science Foundation of China (no. 32171235) and Shanghai Science and Technology Commission, China (no. 19411950902).

AUTHOR CONTRIBUTIONS
X.Z. prepared all the figures and drafted the manuscript. C.S. conceived, supervised, directed the project, and edited the manuscript.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
1. Zhao, X., Hu, S., Zeng, L., Liu, X., Song, Y., Zhang, Y., Chen, Q., Bai, Y., Zhang, J., Zhang, H., et al. (2022). Irradiation combined with PD-L1(-/-) and autophagy inhibition enhances the antitumor effect of lung cancer via cGAS-STING-mediated T cell activation. iScience 25, 104690.
2. Huang, R.X., and Zhou, P.K. (2020). DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct. Target. Ther. 5, 60.
3. Mukherjee, D., Coates, P.J., Lorimore, S.A., and Wright, E.G. (2014). Responses to ionizing radiation mediated by inflammatory mechanisms. J. Pathol. 232, 289–299.
4. Thangamathesvaran, L., Shah, R., Verma, R., and Mahmoud, O. (2018). Immune checkpoint inhibitors and radiotherapy-concept and review of current literature. Ann. Transl. Med. 6, 155.
5. Liu, Y., Dong, Y., Kong, L., Shi, F., Zhu, H., and Yu, J. (2018). Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J. Hematol. Oncol. 11, 104.
6. Park, S.S., Dong, H., Liu, X., Harrington, S.M., Krc, C.J., Grams, M.P., Mansfield, A.S., Furutani, K.M., Oliver, K.R., and Kwon, E.D. (2015). PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol. Res. 3, 610–619.
7. Li, W., Lu, L., Lu, J., Wang, X., Yang, C., Jin, J., Wu, L., Hong, X., Li, F., Cao, D., et al. (2020). cGAS-STING-mediated DNA sensing maintains CD8(+) T cell stemness and promotes antitumor T cell therapy. Sci. Transl. Med. 12, eaay9013.
8. Dewan, M.Z., Galloway, A.E., Kawashima, N., Dewyngaert, J.K., Babb, J.S., Formenti, S.C., and Demaria, S. (2009). Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15, 5379–5388.
9. Zhu, L., Hu, S., Chen, Q., Zhang, H., Fu, J., Zhou, Y., Bai, Y., Pan, Y., and Shao, C. (2021). Macrophage contributes to radiation-induced anti-tumor abscopal effect on transplanted breast cancer by HMGB1/TNF-a signaling factors. Int. J. Biol. Sci. 17, 926–941.